148 related articles for article (PubMed ID: 17970054)
1. Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients.
Sinha AA; Morgan JL; Buus RJ; Ewing SL; Fernandes ET; Le C; Wilson MJ
Anticancer Res; 2007; 27(5A):3135-41. PubMed ID: 17970054
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study.
Sinha AA; Morgan JL; Betre K; Wilson MJ; Le C; Marks LS
Anticancer Res; 2008; 28(4B):2271-7. PubMed ID: 18751406
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
4. Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Prostate; 2001 Sep; 48(4):274-84. PubMed ID: 11536307
[TBL] [Abstract][Full Text] [Related]
5. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of cathepsin B and stefin A expression in Gleason pattern 3+3 (score 6) prostate cancer needle biopsies.
Sinha AA; Morgan JL; Wood N; Betre K; Reddy A; Wilson MJ; Ramanani DM
Anticancer Res; 2007; 27(3B):1407-13. PubMed ID: 17595755
[TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
8. Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis.
Sinha AA; Jamuar MP; Wilson MJ; Rozhin J; Sloane BF
Prostate; 2001 Nov; 49(3):172-84. PubMed ID: 11746262
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease.
Powell IJ; Banerjee M; Novallo M; Sakr W; Grignon D; Wood DP; Pontes JE
Urology; 2000 Feb; 55(2):246-51. PubMed ID: 10688088
[TBL] [Abstract][Full Text] [Related]
10. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
[TBL] [Abstract][Full Text] [Related]
11. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence.
Pettaway CA; Lamerato LE; Eaddy MT; Edwards JK; Hogue SL; Crane MM
BJU Int; 2011 Oct; 108(8):1302-8. PubMed ID: 21371244
[TBL] [Abstract][Full Text] [Related]
12. African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
Kryvenko ON; Balise R; Soodana Prakash N; Epstein JI
J Urol; 2016 Feb; 195(2):301-6. PubMed ID: 26341575
[TBL] [Abstract][Full Text] [Related]
13. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
[TBL] [Abstract][Full Text] [Related]
14. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
15. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.
Pan CC; Lee JS; Chan JL; Sandler HM; Underwood W; McLaughlin PW
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1292-6. PubMed ID: 14630264
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
[TBL] [Abstract][Full Text] [Related]
17. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
[TBL] [Abstract][Full Text] [Related]
18. Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with caucasian prostate cancer patients.
Caruso RP; Levinson B; Melamed J; Wieczorek R; Taneja S; Polsky D; Chang C; Zeleniuch-Jacquotte A; Salnikow K; Yee H; Costa M; Osman I
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):222-7. PubMed ID: 14734473
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.
Tang P; Sun L; Uhlman MA; Robertson CN; Polascik TJ; Albala DM; Donatucci CF; Moul JW
Urology; 2010 Nov; 76(5):1058-62. PubMed ID: 20035982
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.
Crawford ED; Moul JW; Rove KO; Pettaway CA; Lamerato LE; Hughes A
BJU Int; 2011 Dec; 108(11):1743-9. PubMed ID: 21711431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
